• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4596319)   Today's Articles (5329)   Subscriber (49340)
Number Citation Analysis
51
Koh J, Hur J, Lee K, Kim M, Heo J, Ku B, Sun J, Lee S, Ahn J, Park K, Ahn M. P60.09 High Circulating Regulatory (FoxP3+) T Cells and TGF-β Predict the Response to Anti-PD-1 Immunotherapy in NSCLC Patients. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.968] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
52
Goto K, Wolf J, Elamin Y, Santini F, Soldatenkova V, Sashegyi A, Lin AB, Lin B, Novello S, Arriola Aperribay E, Perol M, Loong H, Drilon A, Park K, Solomon B, Zhou C. FP14.05 LIBRETTO-431: Selpercatinib in Treatment-Naïve Patients with RET Fusion-Positive Non-Small Cell Lung Cancer (NSCLC). J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.148] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
53
Veillon R, Sakai H, Le X, Felip E, Garassino M, Cortot A, Smit E, Park K, Griesinger F, Britschgi C, Wu Y, Berghoff K, Otto G, Bruns R, Paik P. FP14.09 Tepotinib Safety in MET Exon 14 (METex14) Skipping NSCLC: Updated Results from the VISION Trial. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.152] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
54
Paik P, Sakai H, Felip E, Veillon R, Garassino M, Raskin J, Viteri S, Mazieres J, Cortot A, Smit E, Thomas M, Cho B, Conte P, Yang J, Morise M, Chen Y, Park K, Gottfried M, Britschgi C, Bruns R, Otto G, Johne A, Le X. MA11.05 Tepotinib in Patients with MET exon 14 (METex14) Skipping Advanced NSCLC: Updated Efficacy Results from VISION Cohort A. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.250] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
55
Cho B, Kim D, Laurie S, Mckeage M, Borra G, Park K, Kim S, Ghosn M, Ardizzoni A, Greystoke A, Izquierdo M, Wang Y, Wang L, Wrona A. P84.05 Efficacy and Safety of Ceritinib 450-mg Fed vs 750-mg Fasted in Patients with ALK+ NSCLC: Final Report of the ASCEND-8 Trial. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.1204] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
56
Lee J, Choi Y, Han J, Park S, Jung H, Sun J, Lee S, Ahn J, Park K, Ahn M. P76.15 Osimertinib Improved Overall Survival in mEGFR NSCLC Patients With Leptomeningeal Metastases Regardless of T790M Mutational Status. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.1072] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
57
Boyer M, Sendur M, Rodríguez-Abreu D, Park K, Lee D, Cicin I, Yumuk P, Orlandi F, Leal T, Molinier O, Soparattanapaisam N, Langleben A, Califano R, Medgyasszay B, Hsia T, Otterson G, Xu L, Piperdi B, Samkari A, Reck M. PS01.09 Pembrolizumab Plus Ipilimumab vs Pembrolizumab Plus Placebo as 1L Therapy for Metastatic NSCLC of PD-L1 TPS ≥50%: KEYNOTE-598. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.322] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
58
Mirazita M, Avakian H, Courtoy A, Pisano S, Adhikari S, Amaryan MJ, Angelini G, Atac H, Baltzell NA, Barion L, Battaglieri M, Bedlinskiy I, Benmokhtar F, Bianconi A, Biselli AS, Bossù F, Boiarinov S, Briscoe WJ, Brooks WK, Bulumulla D, Burkert VD, Carman DS, Carvajal JC, Celentano A, Chatagnon P, Chetry T, Ciullo G, Clary B, Cole PL, Contalbrigo M, Crede V, D'Angelo A, Dashyan N, De Vita R, Defurne M, Deur A, Diehl S, Dilks C, Djalali C, Dupre R, Egiyan H, Ehrhart M, Alaoui AE, Fassi LE, Eugenio P, Fegan S, Fersch R, Filippi A, Forest TA, Ghandilyan Y, Gavalian G, Gilfoyle GP, Giovanetti KL, Girod FX, Glazier DI, Golovatch E, Gothe RW, Griffioen KA, Guidal M, Guo L, Hafidi K, Hakobyan H, Hattawy M, Hayward TB, Heddle D, Hicks K, Hobart A, Holtrop M, Huang Q, Ilieva Y, Ireland DG, Ishkhanov BS, Isupov EL, Jenkins D, Jo HS, Joo K, Keller D, Khanal A, Khandaker M, Kim CW, Kim W, Klein FJ, Kubarovsky V, Kuhn SE, Lanza L, Leali M, Lenisa P, Livingston K, MacGregor IJD, Marchand D, Markov N, Marsicano L, Mascagna V, McKinnon B, Milner RG, Mineeva T, Mokeev V, Mullen C, Camacho CM, Neupane K, Niculescu G, O'Connell T, Osipenko M, Paolone M, Pappalardo LL, Paremuzyan R, Park K, Pasyuk E, Phelps W, Pocanic D, Pogorelko O, Poudel J, Prok Y, Raue BA, Ripani M, Ritman J, Rizzo A, Rossi P, Sabatié F, Salgado C, Schmidt A, Schumacher RA, Sharabian YG, Shrestha U, Soto O, Sparveris N, Stepanyan S, Strakovsky II, Strauch S, Tyler N, Ungaro M, Venturelli L, Voskanyan H, Vossen A, Voutier E, Watts D, Wei K, Wei X, Wood MH, Yale B, Zachariou N, Zhang J, Zhao ZW. Beam Spin Asymmetry in Semi-Inclusive Electroproduction of Hadron Pairs. PHYSICAL REVIEW LETTERS 2021;126:062002. [PMID: 33635681 DOI: 10.1103/physrevlett.126.062002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/26/2020] [Revised: 12/23/2020] [Accepted: 01/12/2021] [Indexed: 06/12/2023]
59
Meyer JM, Lee E, Celli A, Park K, Cho R, Lambert W, Pitchford M, Gordon M, Tsai K, Cleaver J, Arron ST, Mauro TM. CERKL is upregulated in cutaneous squamous cell carcinoma and maintains cellular sphingolipids and resistance to oxidative stress. Br J Dermatol 2021;185:147-152. [PMID: 33393080 DOI: 10.1111/bjd.19753] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/30/2020] [Indexed: 01/16/2023]
60
Karthik R, Pandiselvi K, Mariyappan K, Park K, Kwak IS, Sivakamavalli J. Synthesis of Biogenic Chitosan Biopolymer-Functionalized Zinc-Doped Bi2O3 Nanoneedles and Its Bio-applications: In Vitro Antibacterial and Anticancer activity. ARABIAN JOURNAL FOR SCIENCE AND ENGINEERING 2021. [DOI: 10.1007/s13369-020-05099-w] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
61
Hong D, Bang YJ, Barlesi F, Durm G, Falchook G, Govindan R, Dy G, Park K, Strickler J, Burns T, Kim J, Ang A, Lipford J, Ngarmchamnanrith G, Anderson A, Li B. MO01.31 Durability of Clinical Benefit and Biomarkers in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Sotorasib, a KRAS(G12C) Inhibitor. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2020.10.136] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
62
Chih-Hsin Yang J, Schuler M, Popat S, Miura S, Heeke S, Passaro A, de Marinis F, Park K, Kim E. MO01.36 Afatinib in Asian and Non-Asian Patients (pts) with EGFR Mutation-Positive (EGFRm+) NSCLC Harboring Major Uncommon Mutations. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2020.10.141] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
63
Fuchs M, Almeyda CV, Al Rwahnih M, Atallah SS, Cieniewicz EJ, Farrar K, Foote WR, Golino DA, Gómez MI, Harper SJ, Kelly MK, Martin RR, Martinson T, Osman FM, Park K, Scharlau V, Smith R, Tzanetakis IE, Vidalakis G, Welliver R. Economic Studies Reinforce Efforts to Safeguard Specialty Crops in the United States. PLANT DISEASE 2021;105:14-26. [PMID: 32840434 DOI: 10.1094/pdis-05-20-1061-fe] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
64
Shahamatifard F, Rodrigue D, Park K, Frikha S, Mighri F. Preparation and Characterization of Reduced Graphene Oxide Based Natural Rubber Nanocomposites. INT POLYM PROC 2020. [DOI: 10.1515/ipp-2020-350511] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
65
Meyer JM, Lee E, Celli A, Park K, Cho R, Lambert W, Pitchford M, Gordon M, Tsai K, Cleaver J, Arron ST, Mauro TM. CERKL is Upregulated in Cutaneous Squamous Cell Carcinoma and Maintains Cellular Sphingolipids and Resistance to Oxidative Stress. Br J Dermatol 2020:10.1111/bjd.19707. [PMID: 33270220 PMCID: PMC8172666 DOI: 10.1111/bjd.19707] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
66
Shahamatifard F, Rodrigue D, Park K, Frikha S, Mighri F. Preparation and Characterization of Reduced Graphene Oxide Based Natural Rubber Nanocomposites. INT POLYM PROC 2020. [DOI: 10.3139/217.3987] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
67
Cho B, Loong H, Tsai CM, Teo M, Park K, Kim H, Lee M, Olsen S. 308P The genomic landscape of non-small cell lung cancer (NSCLC) in East Asia using circulating tumour DNA (ctDNA) in clinical practice. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.10.302] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]  Open
68
Yang JH, Schuler M, Popat S, Miura S, Heeke S, Passaro A, de Marinis F, Park K, Kim E. 395P Afatinib in Asian and non-Asian patients (pts) with EGFR mutation positive (EGFRm+) NSCLC harboring major uncommon mutations. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.10.389] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]  Open
69
Diehl S, Joo K, Kim A, Avakian H, Kroll P, Park K, Riser D, Semenov-Tian-Shansky K, Tezgin K, Adhikari KP, Adhikari S, Amaryan MJ, Angelini G, Asryan G, Atac H, Barion L, Battaglieri M, Bedlinskiy I, Benmokhtar F, Bianconi A, Biselli AS, Bossù F, Boiarinov S, Briscoe WJ, Brooks WK, Bulumulla D, Burkert VD, Carman DS, Carvajal JC, Celentano A, Chatagnon P, Chetry T, Ciullo G, Clark L, Cole PL, Contalbrigo M, Crede V, D'Angelo A, Dashyan N, De Vita R, Defurne M, Deur A, Dilks C, Djalali C, Dupre R, Egiyan H, Ehrhart M, El Alaoui A, El Fassi L, Eugenio P, Filippi A, Forest TA, Ghandilyan Y, Gilfoyle GP, Giovanetti KL, Girod FX, Glazier DI, Golovatch E, Gothe RW, Griffioen KA, Guidal M, Guo L, Hakobyan H, Harrison N, Hattawy M, Hayward TB, Heddle D, Hicks K, Holtrop M, Ilieva Y, Ireland DG, Ishkhanov BS, Isupov EL, Jenkins D, Jo HS, Joosten S, Keller D, Khachatryan M, Khanal A, Khandaker M, Kim CW, Kim W, Kubarovsky V, Kuhn SE, Lanza L, Leali M, Lenisa P, Livingston K, MacGregor IJD, Marchand D, Markov N, Marsicano L, Mascagna V, McKinnon B, Meziani ZE, Mineeva T, Mirazita M, Mokeev V, Munoz Camacho C, Nadel-Turonski P, Niculescu G, Osipenko M, Paolone M, Pappalardo LL, Pasyuk E, Phelps W, Pogorelko O, Price JW, Prok Y, Raue BA, Ripani M, Rizzo A, Rossi P, Rowley J, Sabatié F, Salgado C, Schmidt A, Schumacher RA, Sharabian YG, Shrestha U, Soto O, Sparveris N, Stepanyan S, Stoler P, Strakovsky II, Strauch S, Tan JA, Tyler N, Ungaro M, Venturelli L, Voskanyan H, Voutier E, Watts DP, Wei X, Wood MH, Zachariou N, Zhang J, Zhao ZW. Extraction of Beam-Spin Asymmetries from the Hard Exclusive π^{+} Channel off Protons in a Wide Range of Kinematics. PHYSICAL REVIEW LETTERS 2020;125:182001. [PMID: 33196236 DOI: 10.1103/physrevlett.125.182001] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/27/2020] [Revised: 06/08/2020] [Accepted: 07/30/2020] [Indexed: 06/11/2023]
70
Kim M, Park K, Choi I. The metabolic suppressor 3-iodothyronamine enhances lipolysis in 3T3-L1 adipocytes via activation of the adenosine monophosphate-activated protein kinase/forkhead box O1 signaling pathway. JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY 2020;71. [PMID: 33077693 DOI: 10.26402/jpp.2020.3.12] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Subscribe] [Scholar Register] [Received: 05/14/2020] [Accepted: 06/30/2020] [Indexed: 11/03/2022]
71
Hong D, Bang YJ, Barlesi F, Durm G, Falchook G, Govindan R, Dy G, Park K, Strickler J, Burns T, Kim J, Ang A, Lipford J, Ngarmchamnanrith G, Anderson A, Li B. 1257O Durability of clinical benefit and biomarkers in patients (pts) with advanced non-small cell lung cancer (NSCLC) treated with AMG 510 (sotorasib). Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1571] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]  Open
72
Reck M, Spira A, Besse B, Wolf J, Skoulidis F, Borghaei H, Goto K, Park K, Griesinger F, Felip E, Boyer M, Barrios C, Goss G, Yang H, Obiozor C, Ramalingam S. 1416TiP CodeBreak 200: A phase III multicenter study of sotorasib (AMG 510), a KRAS(G12C) inhibitor, versus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC) harboring KRAS p.G12C mutation. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1730] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]  Open
73
Yeo J, Park S, Jung H, Sun JM, Lee S, Ahn J, Park K, Ahn MJ. 1395P Who will maintain as long-term responders more than 3 years with first- or second-generation EGFR TKI among EGFR mutant NSCLC? Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1709] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]  Open
74
Nakagawa K, Nadal E, Garon E, Nishio M, Seto T, Yamamoto N, Park K, Shih JY, Frimodt-Moller B, Zimmermann A, Visseren-Grul C, Reck M. 1294P RELAY, erlotinib plus ramucirumab or placebo in untreated EGFR-mutated metastatic NSCLC: Outcomes by EGFR mutation type. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1608] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]  Open
75
Kim G, Yoon S, Park K, Sohn KY, Kim MH, Kim J. 576P The synergistic anticancer effect of PLAG on the PD-1 immune checkpoint inhibitor in the LLC-1 murine lung carcinoma syngeneic model. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.690] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]  Open
PrevPage 3 of 50 123454950Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA